Central Abdominal Bulging

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Evofem Biosciences
Evofem BiosciencesCA - San Diego
2 programs
2
LIPO-202Phase 31 trial
LIPO-202Phase 31 trial
Active Trials
NCT02398188CompletedEst. Oct 2015
NCT02483533TerminatedEst. Feb 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Evofem BiosciencesLIPO-202
Evofem BiosciencesLIPO-202

Clinical Trials (2)

Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202

Start: Jun 2015Est. completion: Feb 2016
Phase 3Terminated

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

Start: Apr 2015Est. completion: Oct 2015
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space